← All trials
NCT05382312
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2022
- Primary completion
- Sep 22, 2023
- Completion date
- Sep 22, 2023
- First posted
- May 19, 2022
- Last posted
- Nov 7, 2022
- Enrollment
- 55
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
- Click-TB ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.